The following is a summary of “Arrhythmogenic Right Ventricular Cardiomyopathy: the importance of biventricular strain in ...

Arrhythmogenic right ventricular dysplasia/cardiomyopathy was first reported as the partial replacement of the right ventricular myocardium by fat or fibrous tissue. In 1965, researchers described the ...

Differential diagnosis with arrhythmogenic right ventricular cardiomyopathy (ARVC) constitutes a frequent problem, especially in athletes showing ventricular arrhythmias with left bundle branch block ...

Abbreviations: ARVD/C, arrhythmogenic right ventricular dysplasia/cardiomyopathy; VT, ventricular tachycardia. Author's Contributions: P Petrakopoulou and M Greif contributed equally to the ...

The classic ECG findings in arrhythmogenic right ventricular dysplasia are inverted T waves in the right precordial leads (V1-V3) with an epsilon wave after the QRS in lead V1, representing early ...

Over time, repetitive injury may lead to changes that resemble right (or less often) left ventricular (LV) cardiomyopathy, even in the absence of underlying demonstrable genetic abnormalities. The ...

Cardiac sarcoidosis and ACM genetic variants coexist with distinct features, highlighting the need for refined clinical ...

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Tenaya Therapeutics Inc (NASDAQ:TNYA), with a price target of $18.00. This aligns with the strong overall analyst consensus, as ...

Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of ...

Abbreviations: ARVD/C, arrhythmogenic right ventricular dysplasia/cardiomyopathy; VT, ventricular tachycardia. Author's Contributions: P Petrakopoulou and M Greif contributed equally to the ...